UPDATE--CTT Pharmaceutical Holdings, Inc., (CTTH) Announces Canadian Patent for Orally Administrable Nanonized Cannabinoids, ...
February 21 2018 - 10:42AM
CTT Pharmaceutical Holdings, Inc., (OTC:CTTH), an innovative life
sciences company with an extensive portfolio of IP in novel drug
delivery systems, is pleased to announce that the Canadian
Intellectual Property Office has granted Canadian Patent #
2,922,959, titled, “Orally Administrable Composition”, to the
Company. This patent has extremely broad protection for
products such as Oral Thin Films, Wafers, Strips, Tablets, Gums
etc. that deliver active nanonized pharmaceuticals including
Cannabinoids, Opioids and most other large therapeutic molecules.
This newly issued patent expands the Company’s patent
portfolio to five issued (three Canadian and two U.S.) with one
U.S. patent pending and two Worldwide PCT.
“This newly issued patent is the most valuable and difficult to
obtain relative to the other four patents that the Company has been
previously issued,” said Dr. Pankaj Modi, CEO of CTTH. “The claims
allowed are so broad that virtually any entity in Canada that comes
to market with a strip, wafer, tablet, or gum that has any active
therapeutic molecule such as cannabinoids or opioids will be
infringing upon our patent. The nanonization of cannabinoids and
opioids through our Fast Dissolving Oral Thin Film sub-lingual
wafers will provide the Company and its licensed Canadian
distribution partner the opportunity to dominate and monopolize
this industry in Canada. This patent also allows for the
introduction of opioid reduction formulations whereby 10% to
25% of the opioid analgesics dose can be combined with 75% to
90% cannabinoids like THC and/or CBD which would reduce opioid
consumption and overdosing possibilities and improve the safety
profile of daily multiple doses of pain medications.”
The Company’s exclusive Canadian distribution partner, licensed
producer CanniMed Therapeutics Inc. (TSX:CMED) is working toward
obtaining Health Canada’s approval for our sub-lingual CannaWafe
product and upon approval plans to manufacture and commercialize
the technology in Canada for the medical cannabis market. CTT
Pharma is pursuing additional sales and joint venture opportunities
within North America, Europe and Asia through licensing and joint
venture agreements with the objective of bringing its products to
market worldwide.
About CTT Pharmaceutical Holdings, Inc.
CTTH’s principal asset is a unique and novel patented drug
delivery technology, an orally administered, fast dissolving thin
film (the “Wafer”). This technology platform will target both the
human and veterinarian (pet) markets for treatment of many
diseases. The Company believes that its Wafer technology will be
one of the first to gain use in major markets such as pain
management.
The Oral Thin Film (Wafer) formulation is protected by several
Canadian and U.S. patents.
CTTH’s oral fast dissolving drug delivery systems consists of
edible Wafers that dissolve without water and within a few seconds
after placement in the mouth. The majority of drugs administered
using our drug delivery system mirror injections in that they have
the ability to enter the bloodstream quickly, are convenient and
discrete, and can be administered anywhere. A faster
absorption rate is achieved because the mouth contains a very thin
mucosa and is vascular. There is no bitter taste, no smoke
inhalation as is the case with cannabis; less degradation of
medication (by bypassing the stomach) and most importantly lower
dosage units are required given the efficacy of absorption.
Patient compliance is also improved especially with those who
have a fear of choking or difficulty swallowing, and/or are
pediatric, geriatric or incapacitated.
For more information, please visit our
website: www.cttpharmaceuticals.com
Notice Regarding Forward Looking Statements
This news release contains forward-looking statements within the
meaning of applicable securities laws. All statements that are not
historical facts, including without limitation, statements
regarding future estimates, plans, programs, forecasts,
projections, objectives, assumptions, expectations or beliefs of
future performance, are “forward-looking statements”.
Forward-looking statements can be identified by the use of words
such as “plans”, “expects” or “does not expect”, “is expected”,
“estimates”, “intends”, “anticipates” or “does not anticipate”, or
“believes”, or variations of such words and phrases or state that
certain actions, events or results “may”, “could”, “would”, “might”
or “will” be taken, occur or be achieved.
Forward-looking statements are based on assumptions and involve
known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements, including our future sales, income and financial
position. The forward-looking statements included in this news
release are made as of the date of this news release and CTT
Pharmaceutical Holdings not undertake to publicly update such
forward-looking statements to reflect new information, subsequent
events or otherwise, unless required by applicable securities
law.
For more information or to schedule an interview, please
contact:
Dr. Pankaj Modi info@cttpharmaceuticals.com (866) 803 8386